comparison of apremilast and methotrexate in moderate to severe psoriasis patients : a randomized control trial

comparison of efficacy and safety of apremilast and methotrexate in moderate to severe psoriasis : a randomized control trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12625001007426

Enrollment

110

Registered

2025-09-11

Start date

2025-09-15

Completion date

2025-09-30

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

checking the difference in the efficacy and safety of methotrexate and apremilast in moderate to severe psoriasis as methotrexate is contraindicated in pregnancy and also high side effect profile, while apremliast doesn't have such contraindications, yet its efficacy against methotrexate yet to be determined.

Interventions

apremilast ( a phosphodiesterase 4 inhibitor ) orally 30 mg twice daily for 8 weeks. adherence will be checked by observing the no of tablets taken from the pack

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Masking

Blinded (masking used) (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

age between 18-65) both male and female patinets having moderate to severe psoriasis ( PASI score > 10 )

Exclusion criteria

pregnant woman patients with atopic dermatitis patients with concomitant autoimmune disease patients with lichen planus patients with known hypersensitivity to methotrexate or apremilast

Outcome results